







an Open Access Journal by MDPI

Matrix Effectors and Cancer

Guest Editors:

Prof. Dr. Nikos Karamanos

Biochemistry, Biochemical Analysis and Matrix Pathobiochemistry Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26500 Patras, Greece

Dr. Zoi Piperigkou

Biochemistry, Biochemical Analysis & Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26110 Patras, Greece

Deadline for manuscript submissions:

closed (28 February 2021)

Message from the Guest Editors

Dear Colleagues,

Extracellular matrices (ECMs) are highly dynamic threedimensional structural meshworks composed of macromolecules. such proteoglycans/glycosaminoglycans (PGs/GAGs), collagens, laminins, elastin, glycoproteins and proteinases. Matrix macromolecules are characterized by high structural complexity and heterogeneity. They form complex networks through which they dynamically communicate with cells, thus serving as critical regulators of several homeostatic and pathological processes, such as cancer. ECM molecular composition varies among the tissue of origin and it undergoes significant remodeling during cancer progression. The elucidation of the mechanistic aspects governing matrix assembly and cell-matrix interactions is of critical importance to discover matrixmediated cancer pathobiology and novel therapeutic approaches. The aim of this Collection of Cancers is to highlight the emerging roles of effective macromolecules, including matrix metalloproteinases, proteoglycans, specific types of collagens and matrix (glyco)proteins that play key roles in cancer development and aggressiveness.

Prof. Nikos Karamanos Dr. Zoi Piperigkou Collection Editors













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us